← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Femasys Inc. (FEMY) 10-Year Financial Performance & Capital Metrics

FEMY • • Industrial / General
HealthcareMedical InstrumentsSurgical & Interventional DevicesSpecialized Therapeutic Devices
AboutFemasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.Show more
  • Revenue $2M +52.0%
  • EBITDA -$17M -24.4%
  • Net Income -$19M -32.1%
  • EPS (Diluted) -0.84 +9.7%
  • Gross Margin 66.55% +3.1%
  • EBITDA Margin -1038.22% +18.2%
  • Operating Margin -1091.75% +19.3%
  • Net Margin -1155.03% +13.1%
  • ROE -182.18% -114.8%
  • ROIC -276.97% +21.6%
  • Debt/Equity 3.23 +784.5%
  • Interest Coverage -11.09 +87.4%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 11.9%

✗Weaknesses

  • ✗High debt to equity ratio of 3.2x
  • ✗Weak Piotroski F-Score: 2/9
  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 16 (bottom 16%)
  • ✗Shares diluted 44.7% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y11.89%
3Y11.36%
TTM63.53%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-9.38%

EPS CAGR

10Y-
5Y-
3Y-
TTM13.41%

ROCE

10Y Avg-82.22%
5Y Avg-78.17%
3Y Avg-83.95%
Latest-124.53%

Peer Comparison

Specialized Therapeutic Devices
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
RMDResMed Inc.38.05B260.7027.419.84%27.35%23.49%4.37%0.14
ZJYLJin Medical International Ltd.22.54M0.146.1318.57%10.94%16.93%0.41
FEMYFemasys Inc.38.2M0.64-0.7651.97%-9.61%-434.6%3.23
NYXHNyxoah S.A.221.59M5.15-2.853.98%-14.85%-164.31%0.20
MLSSMilestone Scientific Inc.22.8M0.29-4.91-12.19%-76.78%-208.8%0.06
NVCRNovoCure Limited1.55B13.80-8.8518.82%-27.66%-52.05%1.90
EKSOEkso Bionics Holdings, Inc.22.43M8.55-15.27-1.94%-70.74%-107.8%0.47
PLSEPulse Biosciences, Inc.955.52M14.10-15.33-868.99%-80.62%0.08

Profit & Loss

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+929.06K1.04M1.18M1.21M1.07M1.63M
Revenue Growth %-0.12%0.14%0.02%-0.11%0.52%
Cost of Goods Sold+223.68K306.53K370.38K441.94K380.07K544.9K
COGS % of Revenue0.24%0.3%0.31%0.37%0.35%0.33%
Gross Profit+705.39K731.38K809.3K764.28K691.9K1.08M
Gross Margin %0.76%0.7%0.69%0.63%0.65%0.67%
Gross Profit Growth %-0.04%0.11%-0.06%-0.09%0.57%
Operating Expenses+12.34M7.66M9.15M12.36M15.2M18.87M
OpEx % of Revenue13.28%7.38%7.75%10.25%14.18%11.58%
Selling, General & Admin4.8M2.85M4.47M5.99M7.51M10.36M
SG&A % of Revenue5.17%2.75%3.79%4.97%7%6.36%
Research & Development6.91M4.13M4.08M5.81M7.21M8.22M
R&D % of Revenue7.44%3.98%3.46%4.82%6.72%5.04%
Other Operating Expenses625.78K679.65K591.07K561.23K483.48K297.32K
Operating Income+-11.64M-6.93M-8.34M-11.6M-14.51M-17.79M
Operating Margin %-12.53%-6.68%-7.07%-9.62%-13.53%-10.92%
Operating Income Growth %-0.4%-0.2%-0.39%-0.25%-0.23%
EBITDA+-10.54M-5.83M-7.37M-10.71M-13.6M-16.91M
EBITDA Margin %-11.35%-5.62%-6.25%-8.88%-12.69%-10.38%
EBITDA Growth %-0.45%-0.26%-0.45%-0.27%-0.24%
D&A (Non-Cash Add-back)1.09M1.1M964.29K889.14K907.99K872K
EBIT-11.26M-6.9M-7.51M-11.37M-14.08M-17.2M
Net Interest Income+277.56K9.95K-15.46K214.7K265.63K-1.02M
Interest Income287.54K22.5K3.77K228.16K431.02K582.35K
Interest Expense9.97K12.55K19.23K13.46K165.39K1.6M
Other Income/Expense368.24K19.95K802.96K212.39K265.63K-1.02M
Pretax Income+-11.27M-6.91M-7.53M-11.39M-14.24M-18.81M
Pretax Margin %-12.13%-6.66%-6.39%-9.44%-13.29%-11.54%
Income Tax+3.01K1.8K4K6.3K4.34K9.6K
Effective Tax Rate %1%1%1%1%1%1%
Net Income+-11.27M-6.91M-7.54M-11.39M-14.25M-18.82M
Net Margin %-12.13%-6.66%-6.39%-9.45%-13.29%-11.55%
Net Income Growth %-0.39%-0.09%-0.51%-0.25%-0.32%
Net Income (Continuing)-11.27M-6.91M-7.54M-11.39M-14.25M-18.82M
Discontinued Operations000000
Minority Interest000000
EPS (Diluted)+-0.96-0.59-0.64-0.97-0.93-0.84
EPS Growth %-0.39%-0.08%-0.52%0.04%0.1%
EPS (Basic)-0.96-0.59-0.64-0.97-0.93-0.84
Diluted Shares Outstanding11.76M11.76M11.8M11.8M15.38M22.27M
Basic Shares Outstanding11.76M11.76M11.8M11.8M15.38M22.27M
Dividend Payout Ratio------

Balance Sheet

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+8.04M3.86M25.63M14.13M23.18M8.02M
Cash & Short-Term Investments7.41M3.32M24.78M12.96M21.72M3.45M
Cash Only6.42M3.32M24.78M12.96M21.72M3.45M
Short-Term Investments998.83K00000
Accounts Receivable83.55K125.79K84.26K77.47K98.91K488.37K
Days Sales Outstanding32.8344.2426.0723.4433.68109.42
Inventory172.5K131.38K208.27K436.72K667.12K3.05M
Days Inventory Outstanding281.48156.44205.24360.69640.672.04K
Other Current Assets370.02K284.12K555.85K655.36K695.88K1.04M
Total Non-Current Assets+4.61M3.74M2.95M2.76M4.58M4.42M
Property, Plant & Equipment3.86M2.89M2.26M1.8M3.49M3.4M
Fixed Asset Turnover0.24x0.36x0.52x0.67x0.31x0.48x
Goodwill000000
Intangible Assets160.59K65.07K25.09K3.29K065.92K
Long-Term Investments00-20.38M000
Other Non-Current Assets583.5K792.44K655.42K958.18K1.09M954.99K
Total Assets+12.65M7.61M28.58M16.9M27.76M12.45M
Asset Turnover0.07x0.14x0.04x0.07x0.04x0.13x
Asset Growth %--0.4%2.76%-0.41%0.64%-0.55%
Total Current Liabilities+1.29M2.89M1.69M1.53M3.05M8.58M
Accounts Payable481.1K674.33K445.52K510.76K1.14M1.42M
Days Payables Outstanding785.06802.95439.05421.841.09K950.54
Short-Term Debt0630.01K181.12K141.3K05.41M
Deferred Revenue (Current)000000
Other Current Liabilities032.9K54.98K416.73K1.15M88.58K
Current Ratio6.25x1.34x15.15x9.25x7.59x0.93x
Quick Ratio6.12x1.29x15.02x8.96x7.37x0.58x
Cash Conversion Cycle-470.75-602.28-207.73-37.7-418.371.2K
Total Non-Current Liabilities+56.73M1.19M552.21K125.24K6.35M1.56M
Long-Term Debt0182.49K004.26M0
Capital Lease Obligations1.24M809.09K402.42K28.58K2.04M1.52M
Deferred Tax Liabilities0020.38M000
Other Non-Current Liabilities55.49M197.87K149.79K96.66K54.94K39.61K
Total Liabilities58.02M4.08M2.24M1.65M9.4M10.14M
Total Debt+1.71M2.06M990.21K543.72K6.7M7.44M
Net Debt-4.7M-1.27M-23.79M-12.42M-15.02M3.99M
Debt / Equity-0.58x0.04x0.04x0.37x3.23x
Debt / EBITDA------
Net Debt / EBITDA------
Interest Coverage-1166.99x-552.31x-433.62x-861.58x-87.72x-11.09x
Total Equity+-45.37M3.53M26.33M15.24M18.35M2.3M
Equity Growth %-1.08%6.46%-0.42%0.2%-0.87%
Book Value per Share-3.860.302.231.291.190.10
Total Shareholders' Equity-45.37M3.53M26.33M15.24M18.35M2.3M
Common Stock1.06K1.11K11.92K11.99K21.77K23.47K
Retained Earnings-68.29M-75.2M-82.74M-94.13M-108.38M-127.2M
Treasury Stock-60K-60K-60K-60K-60K-60K
Accumulated OCI20702.49K702.49K567.97K2.79M1.86M
Minority Interest000000

Cash Flow

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-11.01M-4.93M-7.93M-10.73M-11.28M-19.44M
Operating CF Margin %-11.85%-4.75%-6.72%-8.9%-10.52%-11.94%
Operating CF Growth %-0.55%-0.61%-0.35%-0.05%-0.72%
Net Income-11.27M-6.91M-7.54M-11.39M-14.25M-18.82M
Depreciation & Amortization1.09M1.1M964.29K889.14K907.99K872K
Stock-Based Compensation358.84K318.64K193.37K224.94K675.7K444.15K
Deferred Taxes003.64K000
Other Non-Cash Items-107.17K4.61K-821.51K6.38K161.39K1.2M
Working Capital Changes-1.08M557.96K-732.72K-458.27K1.22M-3.14M
Change in Receivables3.26K-42.24K41.53K6.79K-21.44K8K
Change in Inventory-34.73K35.32K-77.43K-232.55K-236.28K-2.38M
Change in Payables-13.93K80.75K-228.81K65.24K627.07K207.48K
Cash from Investing+12.32M968.32K-306.87K-407.48K-143.92K-847.76K
Capital Expenditures-696.5K-8.35K-306.87K-407.48K-143.92K-761.71K
CapEx % of Revenue0.75%0.01%0.26%0.34%0.13%0.47%
Acquisitions------
Investments------
Other Investing-103.14K-23.33K000-86.06K
Cash from Financing+-127.78K871.65K29.7M-681.64K20.18M2.03M
Debt Issued (Net)------
Equity Issued (Net)------
Dividends Paid000000
Share Repurchases------
Other Financing-17.07K-75K-1.58M-236.02K2.39M2.35K
Net Change in Cash------
Free Cash Flow+-11.7M-4.96M-8.24M-11.14M-11.42M-20.21M
FCF Margin %-12.6%-4.78%-6.98%-9.24%-10.66%-12.4%
FCF Growth %-0.58%-0.66%-0.35%-0.03%-0.77%
FCF per Share-0.99-0.42-0.70-0.94-0.74-0.91
FCF Conversion (FCF/Net Income)0.98x0.71x1.05x0.94x0.79x1.03x
Interest Paid08.9K15.87K13.46K9.9K111K
Taxes Paid008005.05K4.55K5.71K

Key Ratios

Metric201920202021202220232024
Return on Equity (ROE)--196.01%-50.49%-54.81%-84.82%-182.18%
Return on Invested Capital (ROIC)--229.94%-260.47%-324.4%-353.19%-276.97%
Gross Margin75.92%70.47%68.6%63.36%64.54%66.55%
Net Margin-1213.26%-666.24%-638.97%-944.62%-1329.06%-1155.03%
Debt / Equity-0.58x0.04x0.04x0.37x3.23x
Interest Coverage-1166.99x-552.31x-433.62x-861.58x-87.72x-11.09x
FCF Conversion0.98x0.71x1.05x0.94x0.79x1.03x
Revenue Growth-11.72%13.66%2.25%-11.13%51.97%

Frequently Asked Questions

Growth & Financials

Femasys Inc. (FEMY) reported $2.1M in revenue for fiscal year 2024. This represents a 122% increase from $0.9M in 2019.

Femasys Inc. (FEMY) grew revenue by 52.0% over the past year. This is strong growth.

Femasys Inc. (FEMY) reported a net loss of $19.8M for fiscal year 2024.

Dividend & Returns

Femasys Inc. (FEMY) has a return on equity (ROE) of -182.2%. Negative ROE indicates the company is unprofitable.

Femasys Inc. (FEMY) had negative free cash flow of $20.1M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.